Matinas Biopharma (MTNB) news

Matinas Biopharma - Reverse stock split effective September 28, 2026 - SEC filing

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has announced that a one-for-fifty (1:50) reverse stock split became effective on September 28, 2026, following the completion of necessary regulatory and corporate procedures. The reverse stock split was previously approved by the company’s…

Matinas Biopharma - Board approves reverse stock split at one-for-fifteen ratio - SEC filing

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) has announced that its Board of Directors has approved a reverse stock split at a one-for-fifteen ratio, following a Special Meeting of Stockholders. The proposal was submitted for stockholder approval in a preliminary proxy statement filed with…

Matinas Biopharma - Initial term of agreement expires two years after commercial operations commence

Matinas Biopharma receives notice of non-compliance with NYSE American continued listing standards

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has received a notice of non-compliance with the continued listing standards of the NYSE American. The notice, issued on June 24, 2026, cited the company’s failure to meet the stockholders’ equity requirements outlined in Sections 1003(a)(ii)…

Matinas Biopharma - incurs no termination penalties or expenses from sales agreement termination - SEC filing

Matinas Biopharma Inc. has disclosed in a recent SEC filing that it incurred no termination penalties or expenses following the termination of a sales agreement [1]. The company previously entered into the agreement to facilitate the distribution of one of its pharmaceutical products. According to…